These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 34406816)
1. How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty Pharmacy. Seymour EK; Daniel L; Pointer E; Julian J; Smith ST; Schiffer CA JCO Oncol Pract; 2022 Jan; 18(1):e137-e151. PubMed ID: 34406816 [TBL] [Abstract][Full Text] [Related]
2. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center. Farano JL; Kandah HM J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209 [TBL] [Abstract][Full Text] [Related]
3. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy. Jeong AY; Schwartz EB; Roman AR; McDevitt RL; Oerline MK; Henry E; Veenstra CM; Caram MEV JCO Oncol Pract; 2022 Feb; 18(2):e284-e292. PubMed ID: 34491783 [TBL] [Abstract][Full Text] [Related]
4. 2018 John Charnley Award: Analysis of US Hip Replacement Bundled Payments: Physician-initiated Episodes Outperform Hospital-initiated Episodes. Murphy WS; Siddiqi A; Cheng T; Lin B; Terry D; Talmo CT; Murphy SB Clin Orthop Relat Res; 2019 Feb; 477(2):271-280. PubMed ID: 30664603 [TBL] [Abstract][Full Text] [Related]
5. Differences in the cost of antidepressants across state Medicaid programs. Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875 [TBL] [Abstract][Full Text] [Related]
6. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients. Tseng CW; Brook RH; Keeler E; Mangione CM JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277 [TBL] [Abstract][Full Text] [Related]
7. Net Spending On Retail Specialty Drugs Grew Rapidly, Especially For Private Insurance And Medicare Part D. Hill SC; Miller GE; Ding Y Health Aff (Millwood); 2020 Nov; 39(11):1970-1976. PubMed ID: 33136501 [TBL] [Abstract][Full Text] [Related]
8. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing. Bazalo G; Weiss RC Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986 [TBL] [Abstract][Full Text] [Related]
9. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma. Lee C; Grigorian M; Nolan R; Binder G; Rice G J Med Econ; 2016; 19(4):397-402. PubMed ID: 26652728 [TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125 [TBL] [Abstract][Full Text] [Related]
11. Drug discount cards in an era of higher prescription drug prices: A retrospective population-based study. Munigala S; Brandon M; Goff ZD; Sagall R; Hauptman PJ J Am Pharm Assoc (2003); 2019; 59(6):804-808.e1. PubMed ID: 31422026 [TBL] [Abstract][Full Text] [Related]
12. National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 : A Retrospective Cohort Study. Furukawa NW; Zhu W; Huang YA; Shrestha RK; Hoover KW Ann Intern Med; 2020 Nov; 173(10):799-805. PubMed ID: 32894696 [TBL] [Abstract][Full Text] [Related]
13. Employer drug benefit plans and spending on prescription drugs. Joyce GF; Escarce JJ; Solomon MD; Goldman DP JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957 [TBL] [Abstract][Full Text] [Related]
14. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments. Dickson S; Reynolds I JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176 [TBL] [Abstract][Full Text] [Related]
15. Impact of cost sharing on prescription drugs used by Medicare beneficiaries. Goedken AM; Urmie JM; Farris KB; Doucette WR Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109 [TBL] [Abstract][Full Text] [Related]
16. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans. Clark BE; Siracuse MV; Garis RI Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861 [TBL] [Abstract][Full Text] [Related]
17. Impact of the Medicare modernization act on low-income persons. Havrda DE; Omundsen BA; Bender W; Kirkpatrick MA Ann Intern Med; 2005 Oct; 143(8):600-8. PubMed ID: 16230727 [TBL] [Abstract][Full Text] [Related]
18. Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations. Fiscella RG; Lewis CC; Jensen MK Am J Health Syst Pharm; 2007 Oct; 64(19):2069-73. PubMed ID: 17893419 [TBL] [Abstract][Full Text] [Related]
19. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Lu CY; Law MR; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS Clin Ther; 2011 Jan; 33(1):135-44. PubMed ID: 21397779 [TBL] [Abstract][Full Text] [Related]